Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-5423 (blonanserin) in pediatric schizophrenia
jRCT2080221682Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of blonanserin in schizophrenia (3 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change in total PANSS score from baseline at week 6. Started Dec 2011; status: completed.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221682.